• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

放疗后EBV清除的鼻咽癌患者外周血中表达趋化因子受体CCR1、4和5的CD8 + T细胞频率增加。

Frequency of Peripheral CD8+ T Cells Expressing Chemo-Attractant Receptors CCR1, 4 and 5 Increases in NPC Patients with EBV Clearance upon Radiotherapy.

作者信息

Mahajan Shweta, Balcioglu Hayri E, Oostvogels Astrid, Dik Willem A, Chan K C Allen, Lo Kwok-Wai, Hui Edwin P, Tsang Anna, Tong Joanna, Lam Wai Kei Jacky, Wong Kenneth, Chan Anthony T C, Ma Brigette B Y, Debets Reno

机构信息

Laboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.

Laboratory of Medical Immunology, Department of Immunology, Erasmus MC, 3015 GD Rotterdam, The Netherlands.

出版信息

Cancers (Basel). 2023 Mar 21;15(6):1887. doi: 10.3390/cancers15061887.

DOI:10.3390/cancers15061887
PMID:36980772
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10047204/
Abstract

Radiotherapy (RT) is the standard-of-care for Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC), where the post-RT clearance of plasma EBV DNA is prognostic. Currently, it is not known whether the post-RT clearance of plasma EBV DNA is related to the presence of circulating T-cell subsets. Blood samples from NPC patients were used to assess the frequency of T-cell subsets relating to differentiation, co-signaling and chemotaxis. Patients with undetectable versus detectable plasma EBV DNA levels post-RT were categorized as clearers vs. non-clearers. Clearers had a lower frequency of PD1+CD8+ T cells as well as CXCR3+CD8+ T cells during RT compared to non-clearers. Clearers exclusively showed a temporal increase in chemo-attractant receptors CCR1, 4 and/or 5, expressing CD8+ T cells upon RT. The increase in CCR-expressing CD8+ T cells was accompanied by a drop in naïve CD8+ T cells and an increase in OX40+CD8+ T cells. Upon stratifying these patients based on clinical outcome, the dynamics of CCR-expressing CD8+ T cells were in concordance with the non-recurrence of NPC. In a second cohort, non-recurrence associated with higher quantities of circulating CCL14 and CCL15. Collectively, our findings relate plasma EBV DNA clearance post-RT to T-cell chemotaxis, which requires validation in larger cohorts.

摘要

放射治疗(RT)是爱泼斯坦-巴尔病毒(EBV)相关鼻咽癌(NPC)的标准治疗方法,放疗后血浆EBV DNA的清除情况具有预后意义。目前尚不清楚放疗后血浆EBV DNA的清除是否与循环T细胞亚群的存在有关。我们使用NPC患者的血样来评估与分化、共信号传导和趋化性相关的T细胞亚群的频率。放疗后血浆EBV DNA水平不可检测与可检测的患者分别归类为清除者和未清除者。与未清除者相比,清除者在放疗期间PD1+CD8+T细胞以及CXCR3+CD8+T细胞的频率较低。清除者在放疗时仅表现出趋化因子受体CCR1、4和/或5表达的CD8+T细胞随时间增加。表达CCR的CD8+T细胞增加伴随着幼稚CD8+T细胞减少和OX40+CD8+T细胞增加。根据临床结果对这些患者进行分层后,表达CCR的CD8+T细胞的动态变化与NPC的无复发情况一致。在第二个队列中,无复发与循环中CCL14和CCL15的数量增加有关。总体而言,我们的研究结果将放疗后血浆EBV DNA清除与T细胞趋化性联系起来,这需要在更大的队列中进行验证。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f84e/10047204/63258316a6c8/cancers-15-01887-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f84e/10047204/68f3cd162801/cancers-15-01887-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f84e/10047204/ad31cf6e9c42/cancers-15-01887-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f84e/10047204/ab797a4a68e0/cancers-15-01887-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f84e/10047204/fcde83be9f17/cancers-15-01887-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f84e/10047204/eaa019ab9378/cancers-15-01887-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f84e/10047204/199fd12dcc38/cancers-15-01887-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f84e/10047204/63258316a6c8/cancers-15-01887-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f84e/10047204/68f3cd162801/cancers-15-01887-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f84e/10047204/ad31cf6e9c42/cancers-15-01887-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f84e/10047204/ab797a4a68e0/cancers-15-01887-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f84e/10047204/fcde83be9f17/cancers-15-01887-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f84e/10047204/eaa019ab9378/cancers-15-01887-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f84e/10047204/199fd12dcc38/cancers-15-01887-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f84e/10047204/63258316a6c8/cancers-15-01887-g007.jpg

相似文献

1
Frequency of Peripheral CD8+ T Cells Expressing Chemo-Attractant Receptors CCR1, 4 and 5 Increases in NPC Patients with EBV Clearance upon Radiotherapy.放疗后EBV清除的鼻咽癌患者外周血中表达趋化因子受体CCR1、4和5的CD8 + T细胞频率增加。
Cancers (Basel). 2023 Mar 21;15(6):1887. doi: 10.3390/cancers15061887.
2
Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy.将放疗后血浆 Epstein-Barr 病毒 DNA 与 TNM 分期相结合,对鼻咽癌辅助治疗进行风险分层。
Ann Oncol. 2020 Jun;31(6):769-779. doi: 10.1016/j.annonc.2020.03.289. Epub 2020 Mar 23.
3
Changes in plasma EBV-DNA and immune status in patients with nasopharyngeal carcinoma after treatment with intensity-modulated radiotherapy.鼻咽癌患者调强放疗后血浆EBV-DNA及免疫状态的变化
Diagn Pathol. 2019 Mar 14;14(1):23. doi: 10.1186/s13000-019-0798-0.
4
Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma.循环血浆/血清 EBV DNA 在鼻咽癌临床管理中的应用。
Oral Oncol. 2014 Jun;50(6):527-38. doi: 10.1016/j.oraloncology.2013.12.011. Epub 2014 Jan 15.
5
Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.接受调强放疗的鼻咽癌患者治疗后随访期间血浆 Epstein-Barr 病毒 DNA 水平的预后价值
Chin J Cancer. 2017 Nov 7;36(1):87. doi: 10.1186/s40880-017-0256-x.
6
High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal canrcinoma after radiotherapy.循环中 CD8+CD28- 衰老 T 细胞比例高是鼻咽癌放疗后远处转移的独立预测因子。
J Transl Med. 2023 Jan 31;21(1):64. doi: 10.1186/s12967-023-03912-2.
7
Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma.未分化鼻咽癌放疗后血浆 Epstein-Barr 病毒 DNA 与残留疾病
J Natl Cancer Inst. 2002 Nov 6;94(21):1614-9. doi: 10.1093/jnci/94.21.1614.
8
Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.提出的修改和纳入血浆 Epstein-Barr 病毒 DNA 可改善与 Epstein-Barr 病毒相关的鼻咽癌的 TNM 分期系统。
Cancer. 2019 Jan 1;125(1):79-89. doi: 10.1002/cncr.31741. Epub 2018 Oct 23.
9
GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies.GMP 开发和针对裂解 EBV 抗原的 CAR-T 细胞的临床前验证,用于治疗 EBV 相关恶性肿瘤。
Front Immunol. 2023 Feb 2;14:1103695. doi: 10.3389/fimmu.2023.1103695. eCollection 2023.
10
Circulating lymphocyte subsets are prognostic factors in patients with nasopharyngeal carcinoma.循环淋巴细胞亚群是鼻咽癌患者的预后因素。
BMC Cancer. 2022 Jun 29;22(1):716. doi: 10.1186/s12885-022-09438-y.

本文引用的文献

1
OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum.OX40 激动剂通过改变细胞毒性 T 细胞分化谱增强 PD-L1 检查点阻断。
Cell Rep Med. 2023 Mar 21;4(3):100939. doi: 10.1016/j.xcrm.2023.100939. Epub 2023 Feb 15.
2
Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review.抗 PD-1/PD-L1 治疗复发性或转移性鼻咽癌的临床试验数据:综述。
Cancer Treat Rev. 2022 Sep;109:102428. doi: 10.1016/j.ctrv.2022.102428. Epub 2022 Jun 15.
3
Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma.
肿瘤性程序性死亡配体1(PD-L1)表达与爱泼斯坦-巴尔病毒(EBV)DNA预处理存在情况联合与鼻咽癌患者风险分层及预后的关联
Front Oncol. 2022 Jan 18;11:791411. doi: 10.3389/fonc.2021.791411. eCollection 2021.
4
Anti-PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8 T cells.抗 PD-1 疗效与转移性尿路上皮癌患者肿瘤内 T 辅助 1 型和 CD8 T 细胞毗邻相关。
Clin Cancer Res. 2022 Jan 1;28(1):215-226. doi: 10.1158/1078-0432.CCR-20-3319. Epub 2021 Oct 6.
5
Prognostic Value of Tumor Infiltrating Lymphocytes in Nasopharyngeal Carcinoma Patients: Meta-Analysis.肿瘤浸润淋巴细胞对鼻咽癌患者预后的预测价值:荟萃分析。
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211034265. doi: 10.1177/15330338211034265.
6
Nasopharyngeal carcinoma: an evolving paradigm.鼻咽癌:一个不断发展的范例。
Nat Rev Clin Oncol. 2021 Nov;18(11):679-695. doi: 10.1038/s41571-021-00524-x. Epub 2021 Jun 30.
7
Comprehensive single-cell sequencing reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of nasopharyngeal carcinoma.综合单细胞测序揭示了鼻咽癌微环境中的基质动态和肿瘤特异性特征。
Nat Commun. 2021 Mar 9;12(1):1540. doi: 10.1038/s41467-021-21795-z.
8
Research status and prospects of biomarkers for nasopharyngeal carcinoma in the era of high‑throughput omics (Review).高通量组学时代鼻咽癌生物标志物的研究现状与展望(综述)。
Int J Oncol. 2021 Apr;58(4). doi: 10.3892/ijo.2021.5188. Epub 2021 Mar 2.
9
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells.头颈部鳞状细胞癌患者的新辅助抗 OX40(MEDI6469)治疗可激活和扩增抗原特异性肿瘤浸润 T 细胞。
Nat Commun. 2021 Feb 16;12(1):1047. doi: 10.1038/s41467-021-21383-1.
10
Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution.单细胞分辨率解析的鼻咽癌肿瘤异质性和细胞间网络。
Nat Commun. 2021 Feb 2;12(1):741. doi: 10.1038/s41467-021-21043-4.